Seeking Alpha

Johnson & Johnson (JNJ)

Show Summaries  |  Hide Summaries
  • Aug. 20, 2012, 8:40 AM
    Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment)
  • Aug. 14, 2012, 4:41 PM
    Louis Bacon's Moore Capital - recently making headlines for returning $2B to investors as it can't figure out how to create alpha anymore - sells $700M worth of stocks, including all of its holdings of JPMorgan, Wells Fargo, U.S. Bancorp, an Emerging Market ETF (VWO), and Williams Companies (WMB). The fund took new positions in HYG, JNJ, AGO, and troubled Diamond Foods (DMND).
  • Aug. 14, 2012, 4:40 PM
    Warren Buffett's new positions, according to Berkshire's (BRK.A, BRK.B) latest 13-F, include 27.1M shares of Phillips 66 (PSX) and 2.8M shares of National Oilwell Varco (NOV), but he dumped his entire 7.7M-share position in Intel (INTC) and sold two-thirds of his 29M shares in Johnson & Johnson (JNJ).
  • Aug. 8, 2012, 9:03 AM
    While Pfizer's (PFE) and J&J's (JNJ) bapineuzumab Alzheimer's drug failed in a Phase III trial of people who already exhibit symptoms, scientists may yet test it on those at risk of the disease but aren't yet affected. Pfizer and J&J, though, don't yet have plans to assess bapineuzumab for this purpose.
  • Aug. 6, 2012, 5:33 PM
    Johnson & Johnson (JNJ) down 1.6% and Pfizer (PFE) down 2.1% AH as the companies put a halt on studies of Alzheimer's drug bapineuzumab, which they were developing together but which left execs "disappointed."
    | Comment!
  • Aug. 1, 2012, 10:21 AM
    Pharmacyclics' (PCYC +1.7%) Phase III trial of its ibrutinib drug for treating leukiemia has enrolled a 5th patient, thereby triggering a milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (PR)
    | Comment!
  • Jul. 30, 2012, 10:56 AM
    J&J (JNJ +0.2%) unit Synthes is being sued for wrongful death and negligence by the family of a patient who died in 2003 after she was injected with a bone cement as part of an illegal trial. The suit adds to two other cases brought in the scandal, which saw four execs go to prison.
    | Comment!
  • Jul. 25, 2012, 11:46 AM
    Eli Lilly (LLY +2.7%) CEO John Lechleiter says to use caution when extrapolating the failed clinical trials of Pfizer (PFE -0.5%) and Johnson & Johnson's (JNJ +0.2%) Alzheimer's candidate, bapineuzumab, to solanezumab, the one that [LLY has in its pipeline. "We've got to be very careful before we draw conclusions," Lechleiter says. There are differences between the drugs, how they bond for example, that could allow for different outcomes. The company expects to report clinical data for solanezumab later in Q3.  (Video)
    | Comment!
  • Jul. 23, 2012, 5:33 PM
    Pfizer (PFE) says an experimental Alzheimer's treatment it's working on with Johnson & Johnson (JNJ) unit Janssen Pharmaceuticals did not meet clinical endpoints in a late-stage study. In the study, patients with mild-to-moderate Alzheimer's disease given an intravenous form of the drug bapineuzumab didn't fare any better in cognitive and functional performance than those given a placebo. Elan (ELN), which holds a 49.9% equity interest in Janssen Alzheimer Immunotherapy, is taking a big hit after hours: PFE -1.3%, JNJ -0.2%, ELN -16.8%.
    | 1 Comment
  • Jul. 17, 2012, 11:09 AM
    SA author Stephen Simpson says J&J (JNJ -0.7%) had a decent Q2, with an encouraging underlying performance in the company's drug and orthopedics ops. Simpson's main concern is the devices and diagnostics arms, the latter seeming to be slipping "further and further behind." Still, J&J "looks like a worthwhile name for conservative investors looking for healthcare exposure."
    | Comment!
  • Jul. 17, 2012, 8:12 AM
    More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special items of $2.2B, comprising a write-down related to J&J's Crucell (CRXL) vaccine ops, provision for litigation, costs connected to Synthes acquisition. Cuts 2012 EPS outlook to $5.00-$5.07 from up to $5.17. Consensus is $5.14. Shares -1.4%. (PR)
    | Comment!
  • Jul. 17, 2012, 7:55 AM
    Johnson & Johnson (JNJ): Q2 EPS of $1.30 beats by $0.01. Revenue of $16.5B (-0.7% Y/Y) misses by $200M. Shares -1.2% premarket. (PR)
    | Comment!
  • Jul. 17, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, HST, JNJ, KO, KSU,MAT, MMR, MOS, MTB, OMC, SCHW, STT
    | Comment!
  • Jul. 16, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, HIST, JNJ, KO, KSU,MAT, MMR, MOS, MTB, OMC, SCHW, STT
    | Comment!
  • Jul. 16, 2012, 10:59 AM
    Johnson & Johnson (JNJ): Declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.6%. For shareholders of record Aug 28; Payable Sep 11; ex-div date Aug 24. (PR)
    | Comment!
  • Jul. 12, 2012, 6:06 AM
    J&J (JNJ) could face a bill of almost $4.8B to cover revision surgery for its Pinnacle metal-on-metal hip system, estimates attorney Brian Devine, who is handling cases in which the device has failed. That would add to the $3B J&J has shelled out following the recall of its ASR all-metal artificial hips two years ago.
    | Comment!
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.